EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial

Weihan Zhang, Jing Xue, Jianjun Wang, Dongdong Ni, Wenjing Zhou, Bin Wang, Jinyi Shi, Aihong Wang

Metabolism and Target Organ Damage · 16.03.2026 · 6 (1)

DOI: 10.20517/mtod.2025.210 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 16.03.2026. Verfasst von Weihan Zhang und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study investigated the effects of semaglutide combined with metformin on body weight, glucose and lipid metabolism, sex hormone levels, menstrual cyclicity, and psychological parameters of women living with polycystic ovary syndrome (PCOS)-related infertility and overweight/obesity.

Methods

Sixty-four patients living with infertility and PCOS [body mass index (BMI) ≥ 24 kg/m2] were randomly assigned to standard (n = 32) or semaglutide-intensified treatment groups (n = 32). Both groups underwent lifestyle modification interventions. The standard group received metformin monotherapy [500 mg three times daily (TID)] for 12 weeks, whereas the semaglutide-intensified treatment group received metformin and semaglutide for 12 weeks. An 8-week washout period followed treatment.

Results

The semaglutide-intensified treatment group showed a higher percentage of patients with restored menstrual cycles (86.87% vs. 60.00%, P = 0.038). Significant reductions in luteinizing hormone (LH), androgen levels, and the LH/follicle-stimulating hormone ratio were observed. Greater reductions were also noted in BMI, waist and hip circumference, absolute weight loss, body fat percentage, fasting plasma glucose, fasting insulin, and Homeostatic Model Assessment of Insulin Resistance (P < 0.05). No significant differences were observed in total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels. Psychological distress was not exacerbated in the semaglutide-intensified treatment group.

Conclusion

In women living with PCOS-related infertility and overweight/obesity, semaglutide combined with metformin provided superior improvements in weight reduction, glucose metabolism, insulin sensitivity, and menstrual cyclicity compared with metformin monotherapy, without exacerbating psychological distress. These findings suggest that semaglutide represents a promising therapeutic option for the clinical management of this population.

Zitieren

APA

Zhang, W., Xue, J., Wang, J., Ni, D., Zhou, W., Wang, B., Shi, J., & Wang, A. (2026). Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial. Metabolism and Target Organ Damage, 6(1). https://doi.org/10.20517/mtod.2025.210

Vancouver

Zhang W, Xue J, Wang J, Ni D, Zhou W, Wang B, et al. Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial. Metabolism and Target Organ Damage. 2026;6(1). doi:10.20517/mtod.2025.210

BibTeX
@article{Zhang2026,
  author = {Zhang, Weihan and Xue, Jing and Wang, Jianjun and Ni, Dongdong and Zhou, Wenjing and Wang, Bin and Shi, Jinyi and Wang, Aihong},
  title = {Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial},
  journal = {Metabolism and Target Organ Damage},
  year = {2026},
  volume = {6},
  number = {1},
  doi = {10.20517/mtod.2025.210}
}
Kostenlos starten →